Aurélien Marabelle
Inserm · 911 works · 39,555 citations · h-index 90
Top works
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
- Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
- Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
- Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
- Mechanisms and therapeutic implications of hypermutation in gliomas
- Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- Hyperprogressive disease: recognizing a novel pattern to improve patient management